Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host a virtual event with leading chronic rhinosinusitis (CRS) experts to highlight the Company`s LYR-210 and LYR-220 clinical programs on Wednesday, October 27, 2021 from 2:00 p.m. – 3:00 p.m. ET.

The program will feature presentations by two renowned key opinion leaders in CRS:

• Randall A. Ow, MD, FACS, FARS, FAAOA, FAPCR, is a practicing Otolaryngologist at Sacramento Ear, Nose & Throat and President and Chief Medical Officer of DaVinci Research. Dr. Ow was the principal investigator in the LYR-210 pharmacokinetic study and will provide an overview of the study`s results, which he presented recently at the 67th Annual Meeting of the American Rhinology Society (ARS).
• Zachary Soler, MD, MSc, Associate Professor of Otolaryngology at Medical University of South Carolina (MUSC) and practicing Otolaryngologist at the MUSC Sinus Center. Dr. Soler is a Global Coordinating Principal Investigator for Lyra`s upcoming Phase 3 ENLIGHTEN program for LYR-210, and will provide an overview of the 6-month follow up data from the LANTERN Phase 2 study of LYR-210, which were recently presented at ARS.

During the virtual event, Lyra management will also provide an update on the upcoming Phase 2 BEACON study of LYR-220 and upcoming Phase 3 ENLIGHTEN program for LYR-210. A live webcast and slide presentation will be available in the Investor Relations section of the Company`s website at https://investors.lyratherapeutics.com. The webcast replay will be available following the event.

Lyra has two product candidates in development for the estimated four million CRS patients in the U.S. each year that fail medical management: LYR-210 for surgically naive patients, and LYR-220 for patients who have recurrent symptoms despite surgery. The Company expects to begin its Phase 2 BEACON study for LYR-220 and Phase 3 ENLIGHTEN study for LYR-210 around the end of 2021.

About Lyra Therapeutics 

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra`s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company`s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra`s lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery. Lyra`s second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and post-surgical medical management. For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn and Twitter.